

Research

Open Access

Effects of the estrous cycle, pregnancy and interferon tau on expression of cyclooxygenase two (COX-2) in ovine endometrium

Seokwoon Kim, Youngsok Choi, Thomas E Spencer and Fuller W Bazer*

Address: Center for Animal Biotechnology and Genomics, Department of Animal Science, 442 Kleberg Center, 2471 TAMU, Texas A&M University, College Station, Texas 77843-2471, USA

Email: Seokwoon Kim - swkim@neo.tamu.edu; Youngsok Choi - ychoil@bmc.tmc.edu; Thomas E Spencer - tspencer@ansc.tamu.edu; Fuller W Bazer* - fbazer@cvm.tamu.edu

* Corresponding author

Published: 20 August 2003

Received: 07 July 2003

Reproductive Biology and Endocrinology 2003, 1:58

Accepted: 20 August 2003

This article is available from: <http://www.RBEj.com/content/1/1/58>

© 2003 Kim et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

In sheep, the uterus produces luteolytic pulses of prostaglandin $F_{2\alpha}$ (PGF) on Days 15 to 16 of estrous cycle to regress the corpus luteum (CL). These PGF pulses are produced by the endometrial luminal epithelium (LE) and superficial ductal glandular epithelium (sGE) in response to binding of pituitary and/or luteal oxytocin to oxytocin receptors (OTR) and liberation of arachidonic acid, the precursor of PGF. Cyclooxygenase-one (COX-1) and COX-2 are rate-limiting enzymes in PGF synthesis, and COX-2 is the major form expressed in ovine endometrium. During pregnancy recognition, interferon tau ($IFN\tau$), produced by the conceptus trophoctoderm, acts in a paracrine manner to suppress development of the endometrial epithelial luteolytic mechanism by inhibiting transcription of estrogen receptor α ($ER\alpha$) (directly) and OTR (indirectly) genes. Conflicting studies indicate that $IFN\tau$ increases, decreases or has no effect on COX-2 expression in bovine and ovine endometrial cells. In Study One, COX-2 mRNA and protein were detected solely in endometrial LE and sGE of both cyclic and pregnant ewes. During the estrous cycle, COX-2 expression increased from Days 10 to 12 and then decreased to Day 16. During early pregnancy, COX-2 expression increased from Days 10 to 12 and remained higher than in cyclic ewes. In Study Two, intrauterine infusion of recombinant ovine $IFN\tau$ in cyclic ewes from Days 11 to 16 post-estrus did not affect COX-2 expression in the endometrial epithelium. These results clearly indicate that $IFN\tau$ has no effect on expression of the COX-2 gene in the ovine endometrium. Therefore, antiluteolytic effects of $IFN\tau$ are to inhibit $ER\alpha$ and OTR gene transcription, thereby preventing endometrial production of luteolytic pulses of PGF. Indeed, expression of COX-2 in the endometrial epithelia as well as conceptus is likely to have a beneficial regulatory role in implantation and development of the conceptus.

Background

In ruminants (sheep, cattle and goats), endometrial prostaglandins (PGs) play a major role in regulation of the estrous cycle, pregnancy, and parturition. The estrous cycle of sheep is dependent on the uterus as the source of the luteolysin, prostaglandin $F_{2\alpha}$ (PGF) [see [1,2] for review]. On Days 15 and 16 of the estrous cycle, the cor-

pus luteum (CL) is regressed by luteolytic pulses of PGF [3,4], which are produced by the luminal epithelium (LE) and superficial ductal glandular epithelium (sGE) of the uterine endometrium [5,6]. The coordinated effects of progesterone, estrogen and oxytocin govern the production of luteolytic PGF pulses by the endometrial epithelium [7,8]. Oxytocin, secreted from the posterior pituitary

and CL, binds to oxytocin receptors (OTR) in the endometrium and elicits pulsatile release of PGF from the endometrium [9]. Oxytocin receptor (OTR) mRNA and protein levels increase in endometrial LE and sGE immediately before and during luteolysis (Days 14–16) [10–12]. Estrogen affects the timing, magnitude and pattern of PGF response to oxytocin [13] by acting through estrogen receptor alpha (ER α) to increase OTR gene expression [14–16]. Progesterone initially suppresses ER α and OTR expression in the endometrium, but exposure of the endometrium to progesterone for 8–10 days down-regulates expression of the PR [17]. Consequently, loss of expression of PR in endometrial LE and sGE after Day 11 [18] ends the progesterone block to ER α and OTR formation. Thus, ER α is first detected on Days 11 and 13, which is followed by expression of OTR on Day 14. Increases in the abundance of estrogens from ovarian follicles and ER α promote OTR formation resulting in the pulsatile pattern of PGF release that results in luteolysis [7,13]. Oxytocin binding to the OTR results in cell signaling culminating in the liberation of arachidonic acid, the precursor of PGF.

Prostaglandins are generated via the cyclooxygenase (COX) pathway and COX is the rate-limiting enzyme for conversion of arachidonic acid into prostaglandin H₂ (PGH₂), the common substrate for various PG synthases [18,20]. COX exists in two isoforms that are encoded by two separate genes, *Cox-1* and *Cox-2*, which are also known as prostaglandin endoperoxide H synthases (PGHS)-1 and PGHS-2 [19,20]. These enzymes are responsible for the conversion of arachidonic acid into PGH₂, which is the precursor of various PGs including PGE₂ (PGE) and PGF_{2 α} (PGF). Although COX-1 is a constitutively expressed enzyme in a variety of cell types, COX-2 is the inducible enzyme that plays a role in various pathological and physiological conditions in animal tissues. Although COX-1-deficient female mice are fertile, they have specific defects in parturition, whereas COX-2-deficient female mice are infertile with abnormalities in ovulation, fertilization, implantation and decidualization [21–23]. The requirement of COX-2 for normal blastocyst implantation and decidualization in mice is due to the role of COX-2-derived PGs in regulation of vascular endothelial growth factor (VEGF) and angiopoietin signaling that influence uterine vascular permeability and angiogenesis [24,25].

Abrogation of luteolytic pulses of PGF from the uterus in ruminants is due to effects of conceptus (embryo and associated membranes) signaling [4,26]. Interferon tau (IFN τ), a novel Type I IFN [27], produced by mononuclear trophoblast cells of the ovine conceptus between Days 11 to 20–25, acts in a paracrine manner on the endometrium to inhibit production of luteolytic pulses of

PGF [16,26] by preventing transcription of ER α and OTR genes in LE and sGE [28,29]. Consequently, OTR are absent from endometrial LE and sGE, and OT-induced luteolytic pulses of PGF are abrogated to maintain CL integrity and function. Several *in vitro* studies using bovine endometrial cells led to reports that IFN τ either increases [30,31] or decreases [31–34] expression of COX-2 in bovine endometrial cells. However, Charpigny et al. [5] reported that COX-2 protein in the endometrium was first detectable on Day 12, still expressed on Day 17, and then progressively decreased to Day 25 of pregnancy in sheep, whereas it was only transiently expressed in LE and sGE between Days 12 and 15 of the estrous cycle. In contrast, COX-1 was constitutively expressed in the endometrium of both cyclic and early pregnancy ewes and was not affected by the conceptus [5].

Given the conflicting evidence for IFN τ effects on COX-2 gene expression in the endometrium, objectives of the presented studies were to: (1) determine the effects of the estrous cycle and pregnancy on COX-2 mRNA and protein expression in the ovine endometrium; and (2) determine the *in vivo* effects of IFN τ on COX-2 expression in the ovine endometrium.

Methods

Animals and experimental design

Mature ewes of primarily Suffolk breeding were observed daily for estrous behavior using vasectomized rams. All ewes exhibited at least two estrous cycles of normal duration (16–18 days). At estrus (Day 0), ewes were assigned randomly to cyclic or pregnant status. Ewes assigned to pregnant status were bred to intact rams at estrus. All experiments and surgical procedures were in accordance with the Guide for Care and Use of Agriculture Animals and approved by the University Laboratory Animal Care and Use Committee of Texas A&M University.

In Study One, ewes were hysterectomized (n = 5 ewes/day) on Days 10, 12, 14 or 16 of the estrous cycle and Days 10, 12, 14, 16, or 18 of pregnancy. On Days 10 to 16 post-mating, pregnancy was confirmed by the presence of an apparently normal conceptus in the uterine flushing. At hysterectomy, cross-sections (~0.5 cm) of the uterine horn were fixed in fresh 4% paraformaldehyde in PBS (pH 7.2) for 24 h, dehydrated in 70% (v/v) ethanol for 24 h and then embedded in Paraplast-Plus (Oxford Labware, St. Louis, MO). The remaining endometrial tissues were physically dissected from myometrium, frozen in liquid nitrogen, and stored at -80°C for RNA extraction.

In Study Two, 10 cyclic ewes were ovariectomized and fitted with intrauterine catheters on Day 5 of the estrous cycle (Day 0 = estrus) as described previously [35]. Ewes (n = 5 ewes/treatment) received daily intramuscular

injections of 50 mg progesterone from Days 5 to 16, and then daily intrauterine infusions of either 200 µg control serum proteins (CX; ovine serum proteins) or recombinant ovine IFN τ (IFN; 2×10^7 antiviral units per day) [36] from Days 11 to 16. Preparation of control serum proteins and roIFN τ for intrauterine injection was performed as described previously [35]. The selected dose of roIFN τ mimics pregnancy recognition in terms of ER α , OTR and PG production in response to OT [16,17,28,29] as well as induction and increases in IFN τ -stimulated gene expression in the endometrium [35]. All ewes were hysterectomized on Day 17, and cross-sections from the mid-region of each uterine horn fixed in 4% paraformaldehyde and embedded in paraffin. The endometrium was physically dissected from the remainder of the uterine horns, frozen in liquid nitrogen, and stored at -80°C for RNA extraction.

RNA isolation and analyses

Total cellular RNA was isolated from frozen endometrial tissue using Trizol reagent (Gibco-BRL, Bethesda, MD) according to the manufacturer's recommendations. The quantity of RNA was assessed spectrophotometrically, and integrity of RNA examined by gel electrophoresis in a denaturing 1% agarose gel.

Steady-state levels of COX-2 mRNA were assessed by semi-quantitative RT-PCR analysis as described previously [37]. Briefly, cDNA was synthesized from total cellular RNA (5 µg) isolated from endometrial tissues using random (Life Technologies, Gaithersburg, MD) oligo(dT) primers and SuperScript II Reverse Transcriptase (Life Technologies). Newly synthesized cDNA was acid-ethanol precipitated, resuspended in 20 µl of water, and stored at -20°C. The cDNAs were diluted (1:10) with water before use in PCR. COX-2 PCR primers used (GenBank accession no. U68486) [38] were forward (bp 486–505) 5'-CAGAGCTCTCCTCCTGTGC-3' and reverse (bp 762–780) 5'-CAAAGGCGACGGTTATGC-3'. Using the ovine β -actin mRNA sequence (GenBank accession no. U39357), the β -actin primers were forward (bp 274–295) 5'-CATCCTGACCCCAAGTACCC-3' and reverse (bp 694–674) 5'-GTGGTGGTGAAGCTGTAGCC-3'. The COX-2 PCR reaction consisted of 95°C for 30 sec, 58°C for 30 sec, and 72°C for 30 sec. The β -actin PCR consisted of 95°C for 30 sec, 55°C for 1 min, and 72°C for 1 min. The optimal number of PCR cycles for COX-2 and β -actin was determined to be 32 and 26, respectively, using methods described previously [37]. In negative control reactions, RT cDNA was substituted by inclusion of uterine total RNA or water. The PCR reactions were performed using AmpliTaq DNA polymerase (PE Applied Biosystems Div., Foster City, CA) and Optimized Buffer C (Invitrogen, Carlsbad, CA) for β -actin and COX-2 according to the manufacturer's recommendations. Following PCR, 20 µl

of each reaction was analyzed by agarose gel electrophoresis, and PCR products were visualized using ethidium bromide. The relative amount of DNA present was quantified by measuring the intensity of light emitted from correctly sized bands under ultraviolet light using an Alphamager (Alpha Innotech Corp., San Leandro, CA). The β -actin values were used as a covariate in statistical analyses to correct for differences in the amount of cDNA template between samples. Data are presented as relative units (RU).

In situ hybridization analysis

COX-2 mRNA was localized in uterine tissue sections (5 µm) by *in situ* hybridization analysis as described previously [35]. Briefly, deparaffinized, rehydrated, and deproteinized uterine tissue sections were hybridized with radiolabeled antisense or sense cRNA probes generated from a linearized bovine COX-2 partial cDNA (GenBank AF004944) [29] using *in vitro* transcription with [α -³⁵S] UTP. After hybridization, washing and ribonuclease A digestion, slides were then dipped in NTB-2 liquid photographic emulsion (Kodak, Rochester, NY) and exposed at 4°C for two weeks. Slides were developed in Kodak D-19 developer, counterstained with Harris modified hematoxylin (Fisher Scientific, Fairlawn, NJ) and dehydrated through a graded series of alcohol to xylene. Coverslips were then affixed with Permount (Fisher). Images of representative fields in brightfield and darkfield illumination were recorded using a Nikon Eclipse 1000 photomicroscope (Nikon Instruments Inc., Lewisville, TX) fitted with a Nikon DXM1200 digital camera.

Immunohistochemistry

Expression of immunoreactive COX-2 was detected in uterine tissue cross-sections (5 µm) using anti-human PGHS-2 (COX-2) rabbit polyclonal IgG antibody (PG27, Oxford Biomedical Research, Inc., Oxford, MI) and a Super ABC Rabbit IgG Kit (Biomedex, Foster City, CA) as described previously [35]. Negative controls were performed in which the primary antibody was substituted with the same concentration of purified normal rabbit IgG from Sigma Chemical Co. (St Louis, MO). Sections were deparaffinized, rehydrated, subjected to boiling citrate buffer antigen retrieval [18,35], and then incubated with anti-COX-2 IgG or rabbit IgG. Immunoreactive protein was visualized using diaminobenzidine tetrahydrochloride (Sigma) as the chromogen and then dehydrated and coverslipped over Permount (Fisher Scientific, Pittsburgh, PA).

As described previously [18], relative staining intensity for immunoreactive COX-2 protein expression was assessed visually in uterine sections (n = 2 per horn) from each ewe by two independent observers and scored as follows: absent (-; i.e., no staining above IgG control), weak (+),

moderate (++) , or strong (+++). The scores from the two observers were averaged. If histologically discernable, intercaruncular endometrial tissues, including LE, stroma, and GE, caruncular endometrial tissues, including LE and stroma, and myometrium were scored. Images of representative fields were recorded using a Nikon Eclipse 1000 photomicroscope (Nikon Instruments Inc., Lewisville, TX) fitted with a Nikon DXM1200 digital camera.

Statistical analyses

Integrated light intensity measurement data from RT-PCR analyses were subjected to least-squares analysis of variance (LS-ANOVA) using the General Linear Models (GLM) procedures of the Statistical Analysis System version 8.1 for Windows (SAS Institute, Cary, NC) [38]. The intensity of light emitted from β -actin PCR products was used as the covariate. The least square means (LSM) and standard errors (SE) illustrated in graphs were derived from this analysis. Data is presented as relative units (RU).

Results

Pregnancy increases COX-2 mRNA and protein in the endometrial epithelium

Steady-state levels of COX-2 mRNA in the ovine endometrium were determined by semi-quantitative RT-PCR analyses (Fig. 1). In cyclic ewes, COX-2 mRNA levels increased between Days 10 and 12 and then decreased from Day 12 to Day 16 (quadratic effect of day, $P < 0.10$). In pregnant ewes, endometrial COX-2 mRNA levels were lowest on Day 10, increased approximately 4-fold by Day 12, and remained high thereafter (quadratic, $P < 0.10$).




Figure 1
Steady-state levels of COX-2 mRNA expression in endometrium of cyclic and pregnant ewes. Total RNA was isolated from endometrium and analyzed by semi-quantitative RT-PCR. Data are presented as LSM relative units (RU) with SE.

After Day 10, levels of COX-2 mRNA were greater in the endometrium of pregnant compared to cyclic ewes (day \times status, $P < 0.01$).

In situ hybridization and immunohistochemical analyses revealed temporal and spatial alterations in COX-2 mRNA and protein expression in the ovine uterus. In cyclic (Fig. 2) and pregnant (Fig. 3) ewes, COX-2 mRNA and protein were detected only in LE and sGE of ovine endometrium. In early pregnant ewes (Fig. 3), COX-2 mRNA and protein abundance in endometrial LE and sGE increased from weak to strong between Days 10 and 12 and remained strong to Day 18. The decline in COX-2 expression after Day 12 in the endometrium of cyclic ewes was not observed in the endometrium of comparable pregnant ewes. On Day 18 of pregnancy, COX-2 mRNA and protein were observed in the conceptus.

Intrauterine infusion of ovine IFN τ has no effect on COX-2 expression in the endometrium

In Study Two, intrauterine infusion of rIFN τ into cyclic ewes did not affect ($P > 0.10$) steady-state levels of endometrial COX-2 mRNA as determined by semi-quantitative RT-PCR analysis (data not shown). These results were confirmed by *in situ* hybridization and immunohistochemical analyses of COX-2 mRNA and protein (Fig. 4). COX-2 mRNA and protein were detected predominantly in endometrial LE and were not different in CX as compared to IFN τ infused ewes.

Discussion

In the present study, COX-2 mRNA and protein were detected in endometrial LE and sGE from cyclic ewes. Overall, levels of COX-2 mRNA increased between Days 10 and 12 post-estrus and then decreased. These results conflict with reports that COX-2 protein was expressed maximally in ovine endometrium between Days 10 and 16 of the estrous cycle [40] and that COX-2 mRNA did not fluctuate across the estrous cycle [41]. However, Charpigny et al. [5] found that COX-2 was transiently expressed in the ovine endometrial LE and sGE between Days 12 and 15 of the estrous cycle and then decreased in abundance. The differences in the present study may stem from breed of ewe used in the studies to sensitivity of the biochemical techniques and estrus detection. In bovine studies, COX-2 mRNA and protein were expressed at low and high levels on Days 1–12 and 13–21, respectively, of the estrous cycle [42]. Nevertheless, COX-2 is the predominant enzyme expressed in ovine and bovine uteri [42] and is expressed in LE and sGE of the endometrium, which are responsible for production of luteolytic pulses of PGF2 α [6].

In pregnant ewes, the present study found that COX-2 mRNA and protein expression increased between Days 10




Figure 2

In situ hybridization and immunohistochemical analysis of COX-2 expression in the endometrium of cyclic ewes. Cross-sections of ovine endometrium were hybridized with radiolabeled antisense or sense bovine COX-2 cRNA probes. Hybridized sections were digested with ribonuclease A, and protected transcripts were visualized by liquid emulsion autoradiography. Developed slides were counterstained lightly with hematoxylin, and photomicrographs were taken under bright-field (left) or dark-field illumination (middle). Immunoreactive COX-2 protein was detected using rabbit anti-human COX-2 polyclonal IgG (right). The negative IgG control was performed by substituting irrelevant rabbit IgG for primary antibody. The white arrow denotes areas of specific COX-2 mRNA or immunoreactive protein expression. Legend: C, cyclic; LE, luminal epithelium; S, stroma; sGE, superficial ductal glandular epithelium. Bar = 20 μ m.




Figure 3

In situ hybridization and immunohistochemical analysis of COX-2 expression in the endometrium of early pregnant ewes. Cross-sections of the ovine endometrium were hybridized with radiolabeled antisense or sense bovine COX-2 cRNA probe. Hybridized sections were digested with ribonuclease A, and protected transcripts were visualized by liquid emulsion autoradiography. Developed slides were counterstained lightly with hematoxylin, and photomicrographs were taken under bright-field or dark-field illumination (left). Immunoreactive COX-2 protein was detected using rabbit anti-human COX-2 polyclonal IgG and a BioStain Super ABC Kit (right). The white arrow denotes areas of specific COX-2 mRNA or immunoreactive protein expression. Legend: C, conceptus; LE, luminal epithelium; S, stroma; sGE, superficial ductal glandular epithelium; P, pregnant. Bar = 20 μ m.




Figure 4

In situ hybridization and immunohistochemical analysis of COX-2 expression in the ovine endometrium (Study Two). Ewes were ovariectomized on Day 5 of the estrous cycle, treated daily with progesterone, and infused from Days 11 to 15 with either control (CX) proteins or recombinant ovine IFN τ (IFN). On Day 16, ewes were hysterectomized. Cross-sections of the ovine uterus were hybridized with radiolabeled antisense or sense bovine COX-2 cRNA probe. Hybridized sections were digested with ribonuclease A, and protected transcripts were visualized by liquid emulsion autoradiography. Developed slides were counterstained lightly with hematoxylin, and photomicrographs were taken under bright-field or dark-field illumination (left). Immunoreactive COX-2 protein was detected using rabbit anti-human COX-2 polyclonal IgG (right). The negative IgG control was performed by substituting irrelevant rabbit IgG for primary antibodies. The white arrow denotes areas of specific COX-2 mRNA or immunoreactive protein expression. Legend: CX, control; IFN, interferon tau; LE, luminal epithelium; S, stroma; sGE, superficial ductal glandular epithelium. Bar = 20 μ m.

and 12 and remained high thereafter in the LE and sGE of the endometrium. Charpigny et al. [5] also reported that COX-2 increased on Day 12 of pregnancy and was expressed to Day 17. The present study also detected COX-2 mRNA and protein expression in the Day 18 conceptus. Similarly, Charpigny et al. [5] found that COX-2 was expressed in the ovine conceptus and was developmentally regulated in the trophoblast. The increase in COX-2 expression in ovine endometrium and conceptus is correlated with production of several types of PGs [5,43]. The COX-2-derived PGs produced by the blastocyst are proposed to be involved in blastocyst formation, hatching and elongation [44,45], whereas PGs produced by the

endometrium play essential roles in endometrial vascular permeability and implantation [23–25,46,47].

Conclusions

Several reports supported the hypothesis that IFN τ prevents the COX-2 expression in endometrium to block the production of PGF and that IFN τ acts on endometrium to inhibit OT-stimulated COX-2. Using an *in vitro* model to investigate effects of IFN τ on expression of COX-2, IFN τ was found to decrease COX-2 expression in bovine endometrial cells [32–34]. However, *in vivo* studies showed that expression of COX-2 is essential for blastocyst implantation and decidualization especially changes

in vascular permeability and angiogenesis in mice [23–25]. Thus, available results support the contention that the antiluteolytic effect of IFN τ on endometrial epithelia is not manifest on COX-2 gene expression. Rather, IFN τ inhibits or silences expression of the ER α gene [48], which, in turn, prevents increases in OTR gene expression [49], thereby preventing endometrial production of luteolytic pulses of PGF.

Acknowledgements

We thank the NIH for funding this work (Grant HD32534) and Dr. Michael A. Fortier (University of Laval, Quebec, Canada) for kindly providing the bovine COX-2 cDNA.

References

1. McCracken JA, Custer EE and Lamsa JC: **Luteolysis: a neuroendocrine mediated event.** *Physiol Rev* 1999, **79**:263-323.
2. Spencer TE and Bazer FW: **Biology of progesterone action during pregnancy recognition and maintenance of pregnancy.** *Front Biosci* 2002, **7**:d1879-98.
3. McCracken JA, Carlson JC, Glew ME, Goding JR, Baird DT, Green K and Samuelsson B: **Prostaglandin F $_{2\alpha}$ identified as a luteolytic hormone in sheep.** *Nature New Biol* 1971, **238**:129-134.
4. Hooper SB, Watkins WB and Thorburn GD: **Oxytocin, oxytocin-associated neurophysin, and prostaglandin F $_{2\alpha}$ concentrations in the utero-ovarian vein of pregnant and nonpregnant sheep.** *Endocrinology* 1986, **119**:2590-2597.
5. Charpigny G, Reinaud P, Tamby JP, Créminon C, Martal J, Maclouf J and Guillomot M: **Expression of cyclooxygenase-1 and -2 in ovine endometrium during the estrous cycle and early pregnancy.** *Endocrinology* 1997, **138**:2163-2171.
6. Gray CA, Bartol FF, Taylor KM, Wiley AA, Ramsey WS, Ott TL, Bazer FW and Spencer TE: **Ovine uterine gland knock-out model: effects of gland ablation on the estrous cycle.** *Biol Reprod* 2000, **62**:448-456.
7. McCracken JA: **Hormone receptor control of prostaglandin F $_{2\alpha}$ alpha secretion by the ovine uterus.** *Adv Prostaglandin Thromboxane Res* 1980, **8**:1329-1344.
8. Spencer TE, Ott TL and Bazer FW: **tau-Interferon: pregnancy recognition signal in ruminants.** *Proc Soc Exp Biol Med* 1996, **213**:215-229.
9. Flint AP, Leat WM, Sheldrick EL and Stewart HJ: **Stimulation of phosphoinositide hydrolysis by oxytocin and the mechanism by which oxytocin controls prostaglandin synthesis in the ovine endometrium.** *Biochem J* 1986, **237**:797-805.
10. Ayad VJ, Matthews EL, Wathes DC, Parkinson TJ and Wild ML: **Auto-radiographic localization of oxytocin receptors in the endometrium during the oestrous cycle of the ewe.** *J Endocrinol* 1991, **130**:199-206.
11. Wathes DC and Hamon M: **Localization of oestradiol, progesterone and oxytocin receptors in the uterus during the oestrous cycle and early pregnancy of the ewe.** *J Endocrinol* 1993, **138**:479-491.
12. Stevenson KR, Riley PR, Stewart HJ, Flint AP and Wathes DC: **Localization of oxytocin receptor mRNA in the ovine uterus during the oestrous cycle and early pregnancy.** *J Mol Endocrinol* 1994, **12**:93-105.
13. Beard AP and Lamming GE: **Oestradiol concentration and the development of the uterine oxytocin receptor and oxytocin-induced PGF $_{2\alpha}$ alpha release in ewes.** *J Reprod Fertil* 1994, **100**:469-475.
14. Hixon JE and Flint AP: **Effects of a luteolytic dose of oestradiol benzoate on uterine oxytocin receptor concentrations, phosphoinositide turnover and prostaglandin F-2 alpha secretion in sheep.** *J Reprod Fertil* 1987, **79**:457-467.
15. Burgess KM, Ralph MM, Jenkin G and Thorburn GD: **Effect of oxytocin and estradiol on uterine prostaglandin release in non-pregnant and early-pregnant ewes.** *Biol Reprod* 1990, **42**:822-833.
16. Spencer TE, Becker WC, George P, Mirando MA, Ogle TF and Bazer FW: **Ovine interferon-tau inhibits estrogen receptor up-regulation and estrogen-induced luteolysis in cyclic ewes.** *Endocrinology* 1995, **136**:4932-4944.
17. Spencer TE, Mirando MA, Mayes JS, Watson GH, Ott TL and Bazer FW: **Effects of interferon- τ and progesterone on oestrogen-stimulated expression of receptors for oestrogen, progesterone and oxytocin in the endometrium of ovariectomized ewes.** *Reprod Fertil Dev* 1996, **8**:843-853.
18. Spencer TE and Bazer FW: **Temporal and spatial alterations in uterine estrogen receptor and progesterone receptor gene expression during the estrous cycle and early pregnancy in the ewe.** *Biol Reprod* 1995, **53**:1527-1544.
19. Smith WL, Garavito RM and Dewitt DL: **Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2.** *J Biol Chem* 1996, **271**:33157-33160.
20. Smith WL, Dewitt DL and Garavito RM: **Cyclooxygenases; structural, cellular, and molecular biology.** *Annu Rev Biochem* 2000, **69**:145-182.
21. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ and Czerniak PM: **Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II.** *Nature* 1995, **378**:406-409.
22. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH and Kluckman KD: **Prostaglandin synthase I gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration.** *Cell* 1995, **83**:483-492.
23. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM and Dey SK: **Multiple female reproductive failures in cyclooxygenase-2 deficient mice.** *Cell* 1997, **91**:197-208.
24. Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, Morrow JD, DuBois RN, Trzaskos JM and Dey SK: **Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPAR δ .** *Genes Dev* 1999, **13**:1561-1574.
25. Matsumoto H, Ma WG, Daikoku T, Zhao X, Paria BC, Das SK, Trzaskos JM and Dey SK: **Cyclooxygenase-2 differentially directs uterine angiogenesis during implantation in mice.** *J Biol Chem* 2002, **277**:29260-29267.
26. Fincher KB, Bazer FW, Hansen PJ, Thatcher WW and Roberts RM: **Proteins secreted by the sheep conceptus suppress induction of uterine prostaglandin F-2 alpha release by oestradiol and oxytocin.** *J Reprod Fertil* 1986, **76**:425-433.
27. Roberts RM, Ealy AD, Alexenko AP, Han CS and Ezashi T: **Trophoblast interferons.** *Placenta* 1999, **20**:259-264.
28. Spencer TE, Ing NH, Ott TL, Mayes JS, Becker WC, Watson GH, Mirando MA and Bazer FW: **Intrauterine injection of ovine interferon-tau alters oestrogen receptor and oxytocin receptor expression in the endometrium of cyclic ewes.** *J Mol Endocrinol* 1995, **15**:203-220.
29. Spencer TE and Bazer FW: **Ovine interferon τ suppresses transcription of the estrogen receptor and oxytocin receptor genes in the ovine endometrium.** *Endocrinology* 1996, **137**:1144-1147.
30. Asselin E, Lacroix D and Fortier MA: **IFN-tau increases PGE $_{2}$ production and COX-2 gene expression in the bovine endometrium in vitro.** *Mol Cell Endocrinol* 1997, **132**:117-126.
31. Asselin E, Drolet P and Fortier MA: **Cellular mechanisms involved during oxytocin-induced prostaglandin F $_{2\alpha}$ production in endometrial epithelial cells in vitro: role of cyclooxygenase-2.** *Endocrinology* 1997, **138**:4798-4805.
32. Parent J, Villeneuve C, Alexenko AP, Ealy AD and Fortier MA: **Influence of different isoforms of recombinant trophoblastic interferons on prostaglandin production in cultured bovine endometrial cells.** *Biol Reprod* 2003, **68**:1035-1043.
33. Xiao CW, Murphy BD, Sirois J and Goff AK: **Down-regulation of oxytocin-induced cyclooxygenase-2 and prostaglandin F synthase expression by interferon-t in bovine endometrial cells.** *Biol Reprod* 1999, **60**:656-663.
34. Xiao CW, Liu JM, Sirois J and Goff AK: **Regulation of cyclooxygenase-2 and prostaglandin F synthase gene expression by steroid hormones and interferon- τ in bovine endometrial cells.** *Endocrinology* 1998, **139**:2293-2299.
35. Spencer TE, Stagg AG, Ott TL, Johnson GA, Ramsey WS and Bazer FW: **Differential effects of intrauterine and subcutaneous administration of recombinant ovine interferon tau on the endometrium of cyclic ewes.** *Biol Reprod* 1999, **61**:464-470.

36. Van Heeke G, Ott TL, Strauss A, Ammaturo D and Bazer FW: **High yield expression and secretion of the ovine pregnancy recognition hormone interferon-tau by Pichia pastoris.** *J Interferon Cytokine Res* 1996, **16**:119-126.
37. Stewart MD, Johnson GA, Gray CA, Schuler LA, Burghardt RC, Joyce MM, Bazer FW and Spencer TE: **Prolactin receptor and UTMF expression in the ovine endometrium during the estrous cycle and pregnancy.** *Biol Reprod* 2000, **62**:1779-1789.
38. Zhang V, O'Sullivan M, Hussain H, Roswit WT and Holtzman MJ: **Molecular cloning, functional expression, and selective regulation of ovine prostaglandin H synthase-2.** *Biochem Biophys Res Commun* 1996, **227**:499-506.
39. SAS Institute: *SAS User's Guide: Statistics, Ver 6 Cary, NC: Statistical Analysis System Institute; 1990.*
40. Salamonsen LA and Findlay JK: **Immunocytochemical localization of prostaglandin synthase in the ovine uterus during the oestrous cycle and in early pregnancy.** *Reprod Fertil Dev* 1990, **2**:311-319.
41. Salamonsen LA, Hampton AL, Clements JA and Findlay JK: **Regulation of gene expression and cellular localization of prostaglandin synthase by estrogen and progesterone in the ovine uterus.** *J Reprod Fertil* 1991, **92**:393-406.
42. Arosh JA, Parent J, Chapdelaine P, Sirois J and Fortier MA: **Expression of cyclooxygenases 1 and 2 and prostaglandin synthase in bovine endometrial tissue during the estrous cycle.** *Biol Reprod* 2002, **67**:161-169.
43. Charpigny G, Reinaud P, Tamby JP, Creminon C and Guillomot M: **Cyclooxygenase-2 unlike cyclooxygenase-1 is highly expressed in ovine embryos during the implantation period.** *Biol Reprod* 1997, **57**:1032-1040.
44. Biggers JD, Leonov BV, Baskar JF and Fried J: **Inhibition of hatching of mouse blastocysts in vitro by prostaglandin antagonists.** *Biol Reprod* 1978, **19**:519-533.
45. Sayre BL and Lewis GS: **Arachidonic acid metabolism during early development of ovine embryos: a possible relationship to shedding of the zona pellucida.** *Prostaglandins* 1993, **45**:557-569.
46. Kennedy TG: **Embryonic signals and the initiation of blastocyst implantation.** *Aust J Biol Sci* 1983, **36**:531-543.
47. Psychoyos A, Nikas G and Gravanis A: **The role of prostaglandins in blastocyst implantation.** *Hum Reprod* 1995, **10**(Suppl 2):30-42.
48. Fleming JGW, Choi Y, Bazer FW, Johnson GA and Spencer TE: **Cloning of the ovine estrogen receptor alpha promoter and functional regulation by ovine interferon tau.** *Endocrinology* 2001, **99**:1461-1466.
49. Bazer FW, Fleming JGF, Safe SH and Spencer TE: **The ovine oxytocin receptor promoter/enhancer region is responsive to estrogen receptor alpha.** *Biol Reprod* 2003, **68**(Suppl 1):131 (Abstract 47).

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

